Highlight: Scientific breakdown of cancer reveals promising results

Sep 09, 2010

The chemical structure of the melanoma-shrinking drug PLX4032 is revealed in a new Nature paper that describes the drug’s discovery, development and functioning.

PLX4032 recently showed promising results in an early clinical trial of patients carrying a mutated version of the BRAF gene. Gideon Bollag and colleagues now explain the science behind the success story.

In particular, they note that sufficiently high levels of the drug, which works by blocking the activity of the oncogenic B-RAF , are needed to yield clinical effects, because the ERK signalling pathway, downstream of B-RAF, needs to be almost completely blocked.

The study demonstrates how the design of early clinical trials based on the biological mechanisms underlying tumour formation can speed the translation of anti-cancer drug from laboratory to clinic. And whilst the long-term effects of PLX4032 remain uncertain, it’s hoped that the small molecule inhibitor prove useful in combination with other targeted agents, immunotherapies or chemotherapies.

Explore further: The fine line between breast cancer and normal tissues

More information: Paper: DOI: 10.1038/nature09454

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

The fine line between breast cancer and normal tissues

5 hours ago

Up to 40 percent of patients undergoing breast cancer surgery require additional operations because surgeons may fail to remove all the cancerous tissue in the initial operation. However, researchers at Brigham ...

Pancreatic cancer risk not higher with diabetes Rx DPP-4i

6 hours ago

(HealthDay)—There is no increased short-term pancreatic cancer risk with dipeptidyl-peptidase-4 inhibitors (DPP-4i) compared to sulfonylureas (SU) and thiazolidinediones (TZD) for glycemic control, according ...

Good bowel cleansing is key for high-quality colonoscopy

9 hours ago

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task ...

New rules for anticancer vaccines

10 hours ago

Scientists have found a way to find the proverbial needle in the cancer antigen haystack, according to a report published in The Journal of Experimental Medicine.

User comments : 0